Shares of Opko Health Inc. (NYSE:OPK) ended Friday session in green amid volatile trading. The shares closed up 0.02points or 0.19% at $10.41with 4,186,166.00 shares getting traded. Post opening the session at $10.25, the shares hit an intraday low of $10.13and an intraday high of $10.48 and the price vacillated in this range throughout the day. The company has a market cap of $5.68B and the numbers of outstanding shares have been calculated to be 545.84million shares.
As OPKO Presents Additional data on RAYALDEE at the end of 2016
OPKO Health, Inc. (OPK), declared that additional data on RAYALDEE as a treatment for secondary hyperparathyroidism (SHPT) will be highlighted later today in a poster presentation at the Endocrine Society’s 98th Annual Meeting, underway in Boston, MA. The data showed that mean plasma levels of intact parathyroid hormone (iPTH) and other markers of elevated bone metabolism gradually fell with RAYALDEE treatment as serum total 25-hydroxyvitamin D (25D) rose above 30 ng/mL, a level considered sufficient for chronic kidney disease (CKD) patients in published clinical practice guidelines. No association was apparent between serum calcium or phosphorus and 25D levels rising to >80 ng/mL. These data suggest that patients with stage 3 or 4 CKD require higher levels of serum 25D than previously thought in order to reach vitamin D sufficiency and to optimally control elevated iPTH, and that such levels are well tolerated.
OPKO’s poster presentation entitled “Treatment Effects of Modified-Release Calcifediol on Bone Markers Suggest Higher 25-Hydroxyvitamin D Levels Are Needed for Adequacy in Patients with Stage 3 or 4 CKD,” will be presented by lead author Stuart M. Sprague, DO, Chief, Division of Nephrology and Hypertension, NorthShore University Health System – University of Chicago, Pritzker School of Medicine.
OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, a treatment pending FDA approval for SHPT in stage 3-4 CKD patients with vitamin D insufficiency, and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation approved by FDA and launched by partner Tesaro, IV formulation in Phase 3). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (entering Phase 2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy.
Shares of Horizon Pharma PLC (NASDAQ:HZNP) ended Friday session in green amid volatile trading. The shares closed up 0.80points or 4.83% at $17.37with 3.26million shares getting traded. Post opening the session at $16.43, the shares hit an intraday low of $16.25 and an intraday high of $17.78 and the price vacillated in this range throughout the day. The company has a market cap of $2.65B and the numbers of outstanding shares have been calculated to be 159.88 million shares.
As Horizon Pharma plc, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The companys marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; DUEXIS and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and PENNSAID for the treatment of pain of osteoarthritis of the knees. Its products also include MIGERGOT to treat vascular headache; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus and multiple other indications; and KRYSTEXXA to treat chronic refractory gout. The company has a collaboration agreement with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors for use in the treatment of various forms of cancer. Horizon Pharma plc was founded in 2005 and is headquartered in Dublin, Ireland.
Shares of Eli Lilly and Co (NYSE:LLY) ended Friday session in green amid volatile trading. The shares closed up 1.41points or 1.96% at $73.42with 4,083,598 shares getting traded. Post opening the session at $71.60, the shares hit an intraday low of $71.53and an intraday high of $73.70 and the price vacillated in this range throughout the day. The company has a market cap of $82.68B and the numbers of outstanding shares have been calculated to be 1.10B shares.
As Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of major depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products for the treatment of erectile dysfunction and benign prostatic hyperplasia, thrombotic cardiovascular events, and cardiac ischemic complications. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases.